QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:ENTA

Enanta Pharmaceuticals (ENTA) Stock Forecast, Price & News

$11.81
-0.81 (-6.42%)
(As of 09/21/2023 ET)
Compare
Today's Range
$11.77
$12.61
50-Day Range
$11.81
$19.82
52-Week Range
$11.56
$62.06
Volume
559,427 shs
Average Volume
266,969 shs
Market Capitalization
$248.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.50

Enanta Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
226.0% Upside
$38.50 Price Target
Short Interest
Bearish
8.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.29mentions of Enanta Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($7.24) to ($7.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

194th out of 961 stocks

Pharmaceutical Preparations Industry

79th out of 448 stocks


ENTA stock logo

About Enanta Pharmaceuticals (NASDAQ:ENTA) Stock

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

ENTA Price History

ENTA Stock News Headlines

The Latest Analyst Ratings for Enanta Pharma
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Is NVIDIA Leading a "Magnificent Seven Bubble"?
The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks. 
Jefferies downgrades Enanta Pharmaceuticals (ENTA) to a Hold
Enanta Pharma's Earnings: A Preview
Why Enanta Shares Are Plunging Today
See More Headlines
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Company Calendar

Last Earnings
8/07/2023
Today
9/21/2023
Fiscal Year End
9/30/2023
Next Earnings (Estimated)
11/20/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTA
Employees
160
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.50
High Stock Price Forecast
$87.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+205.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$-121,750,000.00
Net Margins
-163.87%
Pretax Margin
-158.55%

Debt

Sales & Book Value

Annual Sales
$86.16 million
Book Value
$15.51 per share

Miscellaneous

Free Float
18,381,000
Market Cap
$265.78 million
Optionable
Optionable
Beta
0.41
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Jay R. Luly Ph.D. (Age 67)
    Pres, CEO & Director
    Comp: $1.23M
  • Mr. Paul J. Mellett Jr.Mr. Paul J. Mellett Jr. (Age 68)
    Sr. VP of Fin. & Admin. and CFO
    Comp: $650.94k
  • Dr. Yat Sun Or Ph.D. (Age 71)
    Sr. VP of R&D and Chief Scientific Officer
    Comp: $720.16k
  • Mr. Nathaniel S. Gardiner J.D. (Age 69)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $657.95k
  • Dr. Scott T. Rottinghaus M.D. (Age 49)
    Sr. VP & Chief Medical Officer
    Comp: $616.73k
  • Ms. Jennifer Viera
    Sr. Director of Investor Relations & Corp. Communications
  • Dr. Nathalie Adda M.D. (Age 57)
    Consultant
  • Ms. Tara Lynn Kieffer Ph.D. (Age 45)
    Sr. VP of New Product Strategy & Devel.
  • Mr. Brendan Luu (Age 48)
    Sr. VP of Bus. Devel.













ENTA Stock - Frequently Asked Questions

Should I buy or sell Enanta Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View ENTA analyst ratings
or view top-rated stocks.

What is Enanta Pharmaceuticals' stock price forecast for 2023?

8 analysts have issued 1 year target prices for Enanta Pharmaceuticals' shares. Their ENTA share price forecasts range from $14.00 to $87.00. On average, they predict the company's stock price to reach $38.50 in the next year. This suggests a possible upside of 205.1% from the stock's current price.
View analysts price targets for ENTA
or view top-rated stocks among Wall Street analysts.

How have ENTA shares performed in 2023?

Enanta Pharmaceuticals' stock was trading at $46.52 at the beginning of the year. Since then, ENTA stock has decreased by 72.9% and is now trading at $12.62.
View the best growth stocks for 2023 here
.

Are investors shorting Enanta Pharmaceuticals?

Enanta Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,680,000 shares, an increase of 16.7% from the August 15th total of 1,440,000 shares. Based on an average daily trading volume, of 278,600 shares, the days-to-cover ratio is currently 6.0 days. Approximately 8.6% of the shares of the company are short sold.
View Enanta Pharmaceuticals' Short Interest
.

When is Enanta Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 20th 2023.
View our ENTA earnings forecast
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.38) by $0.52. The biotechnology company earned $18.89 million during the quarter, compared to the consensus estimate of $15.88 million. Enanta Pharmaceuticals had a negative net margin of 163.87% and a negative trailing twelve-month return on equity of 46.77%.

What ETF holds Enanta Pharmaceuticals' stock ?

ETFMG Treatments Testing and Advancements ETF holds 5,945 shares of ENTA stock, representing 0.75% of its portfolio.

What guidance has Enanta Pharmaceuticals issued on next quarter's earnings?

Enanta Pharmaceuticals updated its third quarter earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of ($1.86) for the period, compared to the consensus earnings per share estimate of ($2.25). The company issued revenue guidance of $18.9 million, compared to the consensus revenue estimate of $18.19 million.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.71%), State Street Corp (7.21%), Northern Trust Corp (4.63%), Krensavage Asset Management LLC (3.27%), Renaissance Technologies LLC (2.26%) and Dimensional Fund Advisors LP (2.12%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or.
View institutional ownership trends
.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $12.62.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $265.78 million and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($6.31) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

The company employs 160 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530.

This page (NASDAQ:ENTA) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -